Once achalasia is off the table, a normal IRP sends you into the body of the esophagus, which can only fail two ways: too much or too little. This episode is the too-much side: distal esophageal spasm and hypercontractile jackhammer. Both hinge on a normal IRP, both require symptoms to count, and both must clear secondary causes before earning the word diagnosis.

Topics covered

Key decisions

This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.

Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Esophageal Motility

Read this episode: boardpearls.com/gi/episodes/esophageal-motility-ep3

Questions or feedback: [email protected].

• (00:00) - The too-much body

Achalasia is where the manometry numbers point most often, and every strange feature of the disease falls out of one lesion: loss of the inhibitory nerves that relax the sphincter and time the wave. The sphincter clamps but never releases, the body loses its wave, and what the body does on those failed swallows names the subtype. Subtype picks treatment because it changes what the procedure has to accomplish.

Topics covered

Key decisions

This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.

Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Esophageal Motility

Read this episode: boardpearls.com/gi/episodes/esophageal-motility-ep2

Questions or feedback: [email protected].

• (00:00) - One lesion, one disease

Manometry from first principles: every swallow the esophagus has two jobs, the sphincter must open and the body must squeeze in a top-to-bottom wave, and every number the test reports measures one of those two jobs. This episode teaches the order you read them in, sphincter first then body, because that sequence decides which half of the differential you are even in. Master the three numbers here and every motility diagnosis in the chapter becomes a specific pairing of two answers.

Topics covered

Key decisions

This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.

Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Esophageal Motility

Read this episode: boardpearls.com/gi/episodes/esophageal-motility-ep1

Questions or feedback: [email protected].

• (00:00) - Two jobs per swallow: the whole test in one idea

The dysphagias the standard scope-then-manometry workup misses: those after fundoplication and bariatric surgery, and those reaching the esophagus from systemic disease. The unifying skill is knowing which history question surfaces the surgical or systemic story the scope report cannot carry.

Topics covered

Key decisions

This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.

Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Esophageal Symptoms and Diagnostic Workup

Read this episode: boardpearls.com/gi/episodes/esophageal-symptoms-ep3

Questions or feedback: [email protected].

• (00:00) - Introduction: dysphagias the standard workup misses

Episode two of the Esophageal Symptoms chapter covers the complaints that aren't classic dysphagia: globus, rumination, supragastric belching, functional chest pain, and painful swallowing. The unifying tell is a reflux-looking patient who fails real acid suppression, which means the problem was never acid. Diagnosis is made from the history and exposures; the test only confirms it.

Topics covered

Key decisions

This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.

Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Esophageal Symptoms and Diagnostic Workup

Read this episode: boardpearls.com/gi/episodes/esophageal-symptoms-ep2

Questions or feedback: [email protected].

• (00:00) - Intro and the unifying tell

This episode reduces the entire dysphagia workup to two bedside questions, where food sticks and what sticks when, and shows why each answer selects its own test. It sorts oropharyngeal from esophageal dysphagia, maps the solids-versus-mixed and tempo patterns onto specific diagnoses, and clarifies why new dysphagia is itself an alarm symptom that mandates a scope regardless of age.

Topics covered

Key decisions

This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.

Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Esophageal Symptoms and Diagnostic Workup

Read this episode: boardpearls.com/gi/episodes/esophageal-symptoms-ep1

Questions or feedback: [email protected].

• (00:00) - The two bedside questions

GERD 9: PPI-Refractory Heartburn and Series Synthesis

Episode keywords: PPI refractory GERD workup, Spechler NEJM 2019 GERD trial, functional heartburn proportion, fundoplication refractory GERD outcomes, ACG refractory GERD algorithm, GERD diagnosis algorithm, desipramine GERD, baclofen refractory heartburn, systematic GERD workup

Episode Summary

The Spechler NEJM 2019 trial enrolled 366 patients with heartburn persisting on PPIs and systematically worked up every one before randomizing anyone. The result: only 21% had truly PPI-resistant, reflux-related heartburn. More than one in four had functional heartburn with no reflux relationship. Eleven percent responded to PPI optimization alone before the workup even started. The trial shows that systematic evaluation is not a prerequisite for surgery -- it is the treatment. This final episode covers the trial data, the ACG refractory GERD algorithm, and a full synthesis of all nine episodes into the framework boards are actually testing.

Key Topics

• Spechler et al., NEJM 2019: VA study, 366 patients with heartburn persisting on PPI therapy. Step 1: optimize PPI to omeprazole 20 mg twice daily taken 30 to 60 minutes before breakfast and dinner for two weeks. Result: 42 patients (11.5%) responded to optimized PPI alone, never reaching the formal workup. Step 2: the non-responders underwent endoscopy with biopsies, esophageal manometry, and combined impedance-pH monitoring on PPI therapy. Final distribution: 70 patients (19%) unable or unwilling to complete workup; 54 (15%) excluded for miscellaneous reasons; 21 (6.3%) had non-GERD esophageal disorders; 99 (27%) had functional heartburn (normal acid exposure, negative SAP); and 78 (21%) had truly PPI-resistant reflux-related heartburn. One in five patients. That is the denominator for surgical candidates.
• Randomized comparison in confirmed reflux-related refractory heartburn: 78 patients randomized to three arms. Laparoscopic Nissen fundoplication achieved 67% treatment success (at least 50% improvement in GERD-HRQL at one year). Active medical therapy (omeprazole plus baclofen plus desipramine) achieved 28%. Control medical therapy (omeprazole plus placebo baclofen plus placebo desipramine) achieved 12%. Surgery was significantly superior to both medical arms. For the correctly diagnosed patient, fundoplication works. The implication: if you had operated on all 366 patients without the workup, you would have operated on the 27% with functional heartburn, the 11.5% who just needed proper PPI instructions, and the 6.3% with non-GERD disorders. Systematic evaluation is what makes surgery successful, not surgery itself.
• ACG algorithm for refractory GERD: Step 1 -- optimize PPI (correct timing, twice daily, consistent use). Step 2 -- endoscopy. If normal endoscopy and no prior objective GERD confirmation, proceed to ambulatory pH monitoring off PPIs. Step 3 -- if GERD is established and symptoms persist on twice-daily PPI, proceed to combined impedance-pH monitoring on PPIs. For extraesophageal symptoms, antireflux procedures require objective reflux evidence before proceeding.

GERD 8: pH Monitoring, Impedance, and Diagnosing Refractory GERD

Episode keywords: ambulatory pH monitoring GERD, wireless Bravo pH capsule, impedance pH monitoring MII-pH, symptom index reflux, symptom association probability SAP, on versus off PPI pH testing, reflux hypersensitivity diagnosis, acid exposure time normal values, combined impedance pH refractory GERD

Episode Summary

The decision to test on or off PPIs is the most important single judgment call in reflux monitoring, and it follows directly from one question: has GERD been objectively confirmed before? This episode covers the three monitoring platforms (catheter pH, wireless Bravo, combined impedance-pH), the specific clinical scenarios that call for each, the on-versus-off PPI algorithm, and the SI and SAP metrics including their well-documented limitations.

Key Topics

• Indications for ambulatory reflux monitoring: Two broad scenarios. First, heartburn persisting despite optimized PPI therapy where objective characterization is needed. Second, GERD diagnosis has never been objectively established and empiric PPI therapy is being questioned. Atypical presentations (chest pain without heartburn, isolated cough, laryngeal symptoms) also warrant testing when typical GERD symptoms are absent.
• Catheter pH monitoring: pH electrode placed transnasally, positioned 5 cm above the LES, records 24 hours. Measures acid exposure time (percentage of recording period with pH below 4). Abnormal above 6%. Normal below 4%. Indeterminate (grey zone) between 4 and 6%. Foundation platform for reflux diagnosis.
• Wireless Bravo pH monitoring: Capsule clipped to esophageal mucosa during endoscopy, transmits pH wirelessly. Records 48 to 96 hours versus 24, improving diagnostic yield because day-to-day reflux variability is captured. Better patient tolerance means more representative activity patterns. Limitation: measures acid only, no impedance capability.
• Combined impedance-pH monitoring (MII-pH): Nasal catheter with impedance sensors plus a pH electrode. Impedance principle: liquid has low electrical impedance (conducts electricity), air has high impedance. Retrograde liquid bolus produces a characteristic impedance drop propagating proximally. The pH electrode classifies each reflux event as acidic, weakly acidic, or non-acidic. Detects all reflux regardless of acidity -- critical for testing patients on PPI therapy, where acid is suppressed but reflux events still occur at pH-neutral values.
• The on-versus-off PPI decision: If GERD has NOT been objectively established (no prior positive pH study, no prior LA-C or D esophagitis, no documented Barrett's), test OFF PPIs after at least 7 days of discontinuation. The question is whether pathologic reflux exists at all. Testing on PPIs risks false-negative acid suppression. If GERD IS established (prior positive pH study, long-segment Barrett's, prior LA-C or D esophagitis), and symptoms persist on twice-daily PPI, test ON PPIs with combined impedance-pH. The question is why established GERD is not responding. Is there breakthrough acid? Non-acidic reflux with symptom correlation? Or no reflux-symptom association at all? Note: LA-A does not establish GERD. LA-B is borderline. Only LA-C and D represent confirmed erosive disease.
• Symptom Index (SI): Number of symptom episodes within a defined time window of a reflux event divided by total symptom episodes. SI above 50% is positive. Simple but does not account for the baseline probability of overlap when reflux events are very frequent.
• Symptom Association Probability (SAP): Divides the 24-hour recording into 720 two-minute intervals. Marks each for reflux occurrence and symptom report. Applies Fisher's exact test. SAP above 95% is positive. Statistically more sophisticated and adjusts for baseline co-occurrence probability.
• Limitations of both metrics: No study has demonstrated SAP provides better clinical information than SI in predicting treatment outcomes. They frequently disagree. Both depend on patients accurately pressing a symptom button in real time. Both use arbitrary time windows to define association. Neither has been validated as a strong predictor of antireflux therapy response. Boards expect you to know the formulas and cutoffs AND to know these limitations.
• RCT evidence for impedance-pH: A randomized controlled trial demonstrated that treatment decisions guided by impedance-pH results produced better outcomes than empiric management in PPI-refractory heartburn. This moved combined impedance-pH from research tool to evidence-based clinical recommendation for the on-PPI testing scenario.

Board Pearls

GERD 7: NERD -- Non-Erosive Reflux Disease

Episode keywords: non-erosive reflux disease NERD, functional heartburn definition, reflux hypersensitivity, GERD normal endoscopy, dilated intercellular spaces GERD histology, basal zone hyperplasia esophagus, PPI failure categories, EoE masked by PPI, Rome IV functional heartburn

Episode Summary

Up to 70% of GERD patients have no visible mucosal breaks on endoscopy. NERD is not mild GERD or questionable GERD; it is the majority phenotype, with real pathologic acid exposure and real histologic correlates. This episode covers why a normal endoscopy on PPIs cannot classify a patient as NERD, the four categories of PPI failure and why getting the category right determines treatment success, the histology of NERD including a mechanistic revision to the dilated intercellular spaces model, and the treatment distinctions between NERD, reflux hypersensitivity, and functional heartburn.

Key Topics

• NERD definition: Troublesome reflux-related symptoms in the absence of endoscopically visible mucosal breaks. Pathologic acid exposure or positive symptom-reflux correlation is present. NERD is not "no GERD" -- it is a distinct phenotype within the GERD spectrum.
• Clinical diagnosis without endoscopy: The ACG states that a patient with typical heartburn who responds completely to acid suppression has a clinical diagnosis of GERD without requiring endoscopy. Endoscopy in this population is for Barrett's screening, not to confirm GERD.
• The NERD misclassification trap: To classify a patient as NERD, endoscopy must be performed off PPIs. A normal endoscopy while on active PPI therapy does not establish NERD -- it may simply mean the PPI healed existing erosions. This is also the scenario where EoE can be missed: PPIs suppress EoE features (rings, furrows, eosinophilic infiltration) completely. The guideline recommendation is to stop PPIs 2 to 4 weeks before endoscopy when EoE is a diagnostic consideration.
• Four categories of PPI failure: Category 1 -- the problem is not esophageal (cardiac chest pain, biliary disease masquerading as heartburn). Category 2 -- esophageal but not GERD (EoE causing chest pain and dysphagia, achalasia producing regurgitation labeled as reflux). Category 3 -- reflux-related, but either acid is genuinely persisting despite PPI (timing, adherence, or PPI-resistant acid production) OR physiologically normal reflux is perceived as painful (reflux hypersensitivity). Category 4 -- functional heartburn (no temporal relationship between symptoms and reflux events, normal acid exposure, negative symptom association). Treatment is completely different for each category.
• NERD histology: Elongated papillae (finger-like lamina propria projections extending beyond two-thirds of epithelial thickness), basal zone hyperplasia (proliferative layer exceeding 15% of epithelial thickness), and inflammatory cell infiltration consistent with the cytokine-mediated injury model from Episode 1. Dilated intercellular spaces (DIS) are visible on both electron microscopy and standard H&E staining; mean intercellular space diameter is measurably greater in NERD patients versus controls.
• DIS mechanism revision: The traditional explanation was that acid and pepsin directly damage tight junctions, increasing paracellular permeability. More recent data suggests cytokine-induced damage to mucosal microvasculature causes vascular fluid extravasation into intercellular spaces. The mechanism is inflammatory vascular leakage, not acid dissolving cell adhesion.
• Reflux hypersensitivity: Normal acid exposure time on ambulatory pH monitoring but positive symptom-reflux association (positive SI or SAP). The reflux is physiologic; the perception is pathologic. Rome IV classifies this as a functional esophageal disorder driven by peripheral or central visceral sensitization. Treatment shifts toward neuromodulators. More acid suppression will not help because acid quantity is not the problem.
• PPI response in NERD: Approximately 37% symptomatic response at 4 weeks versus 56% in erosive GERD. However, this gap is largely explained by study contamination: NERD trials often failed to exclude functional heartburn patients, who by definition will not respond to acid suppression. Baclofen may help patients where non-acidic reflux plays a prominent role.

Board Pearls

GERD 6: Pregnancy, Atypical GERD, and the LPR Controversy

Episode keywords: GERD in pregnancy, famotidine pregnancy GERD, LPR laryngopharyngeal reflux controversy, extraesophageal GERD symptoms, PPI safety pregnancy, laryngeal erythema nonspecific, LPS LPRD consensus terminology, empiric PPI atypical symptoms

Episode Summary

Two-thirds of pregnant women experience heartburn, and the treatment hierarchy is strictly ordered. But the more contentious territory is what happens when reflux is blamed for laryngeal, pharyngeal, and pulmonary symptoms. A recent consensus conference recommended retiring the term "laryngopharyngeal reflux" and replacing it with a framework that separates symptoms from proven disease. Laryngoscopic findings of erythema are found in over 90% of healthy controls, which means the most common tool used to diagnose LPR has essentially no specificity. This episode covers why PPIs do not reliably help extraesophageal symptoms without concurrent typical GERD, and when objective reflux testing is required before treatment.

Key Topics

• GERD in pregnancy -- step-up approach: Heartburn affects approximately two-thirds of pregnant women. Progesterone relaxes the LES; growing uterus increases intra-abdominal pressure. Treatment order: (1) lifestyle modifications and smaller meals; (2) antacids (aluminum, calcium, magnesium-based are safe) and alginates; (3) sucralfate (not systemically absorbed); (4) H2 receptor antagonists if needed, with famotidine preferred for breastfeeding patients due to lowest breast milk concentration; (5) PPIs as next step if required.
• PPI safety in pregnancy -- historical category distinction: Under the former FDA letter system, all PPIs were category B except omeprazole, which was category C (animal studies showed some adverse effect without adequate human data). The FDA has since retired letter categories in favor of descriptive labeling, but boards still test this historical distinction. Omeprazole was the sole category C PPI. Esomeprazole strontium and magnesium-containing formulations should be avoided in pregnancy and lactation. Vonoprazan has no adequate pregnancy data; manufacturer advises against breastfeeding while taking it.
• Atypical and extraesophageal GERD presentations: Chronic laryngitis, chronic cough, asthma exacerbation, globus sensation, sore throat, burning tongue, dental erosions, chronic sinusitis, and non-heartburn chest pain. Two mechanisms: direct contact (acid reaches the larynx, which is far more acid-sensitive than the esophagus) and vagally mediated reflexes (acid in the distal esophagus triggers cough or bronchospasm without reaching the throat).
• The LPR terminology shift: A recent consensus conference recommends retiring "laryngopharyngeal reflux (LPR)" as a diagnosis. The new framework distinguishes laryngopharyngeal symptoms (LPS, the clinical presentation: cough, voice changes, throat clearing, phlegm sensation) from laryngopharyngeal reflux disease (LPRD, which requires objective evidence that reflux is causing those symptoms). Laryngoscopy cannot establish LPRD.
• Laryngoscopic findings are nonspecific: Laryngeal erythema and edema attributed to acid damage are found in over 90% of healthy normal controls. A positive laryngoscopy for reflux changes has virtually no specificity. What laryngoscopy does accomplish is excluding other oropharyngeal pathology (vocal cord lesions, masses, structural abnormalities) rather than confirming a reflux etiology.
• The data problem: Approximately 50% of patients carrying an LPR diagnosis have normal acid exposure on conventional ambulatory pH monitoring. Proximal esophageal and pharyngeal pH monitoring have consistently failed to distinguish suspected LPR patients from healthy controls.
• PPI response for extraesophageal symptoms: Non-cardiac chest pain with objective evidence of acid reflux responds well (56 to 85% benefit). For throat clearing, hoarseness, and chronic cough without concomitant typical GERD, randomized placebo-controlled trials have not shown consistent PPI benefit over placebo. The AGA advises against empiric PPI trials for extraesophageal symptoms without concomitant typical GERD symptoms. ACG recommends non-GERD causes be evaluated first (ENT for hoarseness, pulmonology and upper airway cough syndrome workup for cough) and reflux testing performed before initiating PPI therapy when typical GERD is absent. When extraesophageal symptoms accompany daily heartburn, an 8 to 12 week trial of twice-daily PPI is reasonable.
• Surgery for extraesophageal symptoms: Only consider antireflux surgery or endoscopic antireflux procedures in patients with objective evidence of reflux. Fundoplication does not reliably improve laryngopharyngeal symptoms in patients already failing PPI therapy. If PPIs (which dramatically reduce acid) are not helping, acid is likely not the cause, and mechanical prevention of reflux will not help either.

Board Pearls